Prime Medicine cleared its Prime Editor program for clinical testing in Wilson’s disease after receiving clearance from Medsafe, New Zealand’s medicines regulator. The company’s investigational PM-577a received approval for a clinical trial application, moving the program closer to first-in-human evaluation. Prime editing (a precise DNA or RNA modification approach) is designed to change genetic information while avoiding double-strand breaks associated with some genome-editing platforms. Prime Medicine’s filing signals regulatory readiness to begin structured evaluation of PM-577a in Wilson’s disease. For the field, Medsafe clearance adds momentum to clinical prime editing programs and expands the number of in-progress regulatory pathways for next-generation gene modification therapies.